DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting Nov 21, 2017
DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Component of Combination Chemotherapy Regimens for the Treatment of Solid Tumors including Brain and Ovarian Cancer Oct 31, 2017
DelMar Pharmaceuticals Presents Poster at AACR's Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer Oct 3, 2017
DelMar Pharmaceuticals Announces Closing Of $10 Million Registered Direct Offering Priced At-The-Market Sep 22, 2017
DelMar Pharmaceuticals Announces $10 Million Registered Direct Offering Priced At-The-Market Sep 20, 2017
DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083 Sep 20, 2017
